A medicine can secure regulatory approval and reimbursement authorization and still be out of reach for many eligible patients. Such decisions create the formal possibility of treatment access; they do not ensure that eligible patients can obtain therapy promptly or consistently in routine care. Patient access can also be limited by factors like affordability, treatment usability, logistical complexity, restricted service availability, and other preventable barriers.
For healthcare providers and regulatory decision-makers, the crucial post-launch question is, thus, not merely whether a medicine is approved or reimbursed, but whether eligible patients can successfully move from identifying a health need to receiving and benefiting from suitable treatment. It is equally important to evaluate if this access pathway operates equitably across different patient populations.
A patient-centred access framework defines access as the opportunity for individuals to identify a health need, seek care, reach the relevant services, obtain and use treatment, and have that health need appropriately addressed. The framework assesses access along five interconnected dimensions: approachability, acceptability, availability and accommodation, affordability, and appropriateness. These dimensions capture both the characteristics of the healthcare system and patients’ capacity to perceive, seek, reach, pay for, and engage with care.
Coverage is Potential Access, Not Realised Access
Generally, coverage means that a payer, insurer, or health system will pay for a medicine as long as certain conditions are met. These conditions may include prior authorisation, step therapy, diagnostic confirmation, specialist prescribing, quantity limits, the need for renewal, or a requirement that the medicine be used in a particular treatment line.
The patient access journey is quite extensive:
Need→ Diagnosis→ Prescription→ Authorisation→ Dispensing or administration→ Treatment initiation→ Continuation
A covered medicine can lose patients at every stage. A patient may be clinically eligible but not diagnosed; prescribed but not authorised; approved but unable to afford the copayment. Alternatively, the medicine may be dispensed but inaccessible because of treatment-centre barriers, or started but discontinued due to treatment burden.
This is the reason why coverage should be regarded as potential access, while treatment initiation and continued appropriate use represent realised access. Research that applies patient-centred access frameworks also cautions against considering healthcare utilisation as evidence of access. In short, access to treatment depends not only on whether a medicine is covered, but also on whether the healthcare system and patients can support its use.
For post-launch assessment, the key distinction is:
- Coverage: The system has established a route to treatment.
- Realised access: The patient has successfully used that route.
- Quality of access: The route is timely, affordable, appropriate, usable, and equitable.
What Defines Quality of Patient Access?
The quality of access should be evaluated based on four connected dimensions: timeliness, usability, affordability, and appropriateness and equity.
-
Timely access
Timely access refers to patients receiving treatment within a clinically appropriate period for their condition. Assessment should consider not only whether treatment is approved, but also how long patients wait before receiving it.
Useful indicators include:
- Median time from prescription to authorisation.
- Median time from authorisation to first dispense or administration.
- Percentage of patients delayed beyond a predefined clinical threshold.
- Time from diagnosis to treatment initiation.
- Number and duration of authorisation appeals.
- Waiting time for specialist appointments, diagnostic tests, or treatment sites.
When considering time, it should be interpreted relative to the disease urgency. A two-week delay may lead to different implications for a chronic condition requiring recurring treatment than for aggressive cancer or a rapidly progressing rare disease.
-
Usable access
A therapy is not genuinely accessible to patients and providers if they are unable to go through the process needed to obtain it. Usability may be limited by complex authorisation forms, repeated requests for documentation, specialist-only prescribing, restricted distribution channels, testing or monitoring requirements, limited infusion capacity, and poor communication among healthcare stakeholders.
Measures should include:
- The rate of incomplete submissions
- Failed pharmacy transfers
- Unresolved support cases, scheduling failures
- Time spent by providers or patients completing access requirements.
The dimension is particularly relevant for specialty medicines; since the treatment process may involve a number of organisations rather than a single dispensing event.
-
Affordable access
Just because reimbursement is provided doesn’t mean that the treatment is affordable for the patient, as their actual financial liability could consist of deductibles, copayments, coinsurance, administration charges, diagnostic costs, travel expenses, and time off from work.
Recommended measures include:
- Patient out-of-pocket cost at treatment initiation.
- Monthly or annual treatment-related cost.
- Cost-related prescription abandonment.
- Percentage of patients requiring financial assistance.
- Assistance approval and renewal rates.
- Financial burden by income, insurance type, or geography.
- Patient-reported difficulty paying for treatment-related services.
WHO frameworks treat affordability as distinct from physical availability, stressing that medicines must be priced at a level individuals and communities can pay. They also describe availability, affordability, quality, and appropriate use as interconnected components of medicine access.
-
Appropriate and equitable access
The quality of access also varies according to whether the eligible patients receive the treatment best suited to their needs through the appropriate care pathway.
This requires assessing:
- Use within the approved indication.
- Appropriate diagnostic or biomarker confirmation.
- Alignment with clinical guidelines.
- Correct dose, duration, and monitoring.
- Continuity between prescribing, dispensing, administration, and follow-up.
- Access differences across regions, care settings, income groups, age groups, and insurance categories.
Equal start rates don’t mean equal access. If one region has far more patients in need, the same rate still leaves more patients untreated. The comparison should consider need, eligibility, and expected treatment benefit.
How to Measure the Patient Access Gap?
A practical post-launch scorecard should track the points at which eligible patients are lost.
| Access stage | Core question | Suggested indicator |
|---|---|---|
| Eligibility | Are patients who may benefit being identified? | Diagnosis, testing, and eligibility rate |
| Prescription | Are appropriate eligible patients being prescribed treatment? | Eligible-patient prescription rate |
| Authorisation | Is coverage converting into approval? | Approval, denial, and appeal rates |
| Fulfilment | Can approved patients obtain the product? | Dispense or administration completion rate |
| Initiation | Does the patient receive the first dose? | Authorisation-to-start conversion |
| Continuation | Can the patient remain on therapy? | Persistence, refill continuity, or administration completion |
| Equity | Are barriers concentrated in particular groups? | Differences in delay, denial, abandonment, and initiation |
| Patient experience | Is the pathway acceptable and manageable? | Reported affordability, burden, navigation, and satisfaction |
At each step, the drop-off rate is calculated. This allows manufacturers to identify whether the biggest access gap is driven by diagnosis, prescribing, payer restrictions, affordability, fulfilment, treatment burden or another barrier.
In many settings, the most valuable metric is often authorisation-to-start conversion, because it isolates patients who were approved but did not begin treatment. However, this measure should not be interpreted without knowing why patients didn’t start. A non-start may result from payer denial, patient affordability, product unavailability, administrative delay, clinical deterioration or contraindication, a physician’s decision to use another therapy, patient preference, and incomplete or inaccurate data.
The difference is essential. A lower start rate caused by informed clinical choice is not the same as a lower start rate caused by an avoidable administrative barrier.
A useful measurement model is:
| Start rate = | Patients receiving first treatment / Patients with a valid prescription or treatment decision |
|---|
For a more complete view:
| Effective access = | Eligibility × Timeliness × Affordability × Availability × Appropriate use |
|---|
It should be treated as a conceptual model, not as an automatically aggregated score since, as the various factors are multiplied, a low value in any one of them pulls down the whole result.
Post-launch Priorities for Decision Makers
-
For pharmaceutical executives
The management of post-launch access should be treated as a cross-functional performance issue and not be left solely to the market access or patient-support teams.
Leadership should:
- Clearly define coverage, approval, dispensing, treatment initiation, abandonment, and persistence in the same way each time.
- Monitor the entire pathway according to payer, region, indication, channel, and patient segment.
- Determine the very first point at which the patient drops off.
- Separate the system barriers from clinical decisions and patient choice.
- Track the actual out-of-pocket cost rather than relying on the list price or reimbursement status.
- Combine claims, electronic health records (EHRs), specialty pharmacy services, patient support services, and patient-reported data.
- Set limits for delays, cases of abandonment, and equity gaps which will cause a response to be triggered if these limits are exceeded.
The objective is to ensure that appropriate, eligible patients receive the treatment they need without being prevented by avoidable system barriers.
-
For regulators and HTA decision makers
Post-launch monitoring can test whether a reimbursement decision is producing the access that it intended to create.
Relevant questions include:
- Are coverage restrictions delaying clinically appropriate treatment?
- Do administrative requirements match what they’re meant to protect?
- Are rural or underserved patients experiencing longer delays?
- Is the medicine available in the facilities and channels required for its use?
- Are affordability barriers reducing uptake among eligible patients?
- Does real-world use align with the evidence and population taken into account during assessment?
- Are managed-entry or conditional-reimbursement commitments being fulfilled?
- Are the conditions or commitments related to reimbursement being met?
This links access measurement to real-world evidence and reassessment. It also supports a more balanced policy discussion: restrictions may protect budgets and promote appropriate use, but excessive friction can prevent timely treatment.
How Ingenious e-Brain Can Help Close the Access Gap
Turning coverage into realised access takes sound evidence. It includes a clear understanding of how payers decide and when eligible patients drop off. Ingenious e-Brain supports pharma R&D and commercialization teams across the patient access journey, including rare disease and orphan drugs, with:
- Access journey assessment: We map the path from need to continuation and pinpoint where eligible patients are lost.
- Payer and HTA insight: Our panel of 4,500+ payers helps show how coverage conditions work in practice.
- Real-world evidence: We design RWE approaches to track initiation, persistence, and use against the approved population.
- Affordability and pricing: We assess price, budget impact, patient out-of-pocket burden, and managed access options together.
- Global and equity view: We compare access across markets, regions, and patient groups with different HTA and reimbursement pathways.
Conclusion
Coverage is an important foundation, but it is not the final measure of patient access… Quality of access is demonstrated when eligible patients can identify and obtain appropriate treatment within a clinically acceptable timeframe, afford the full treatment pathway, navigate it successfully, and continue therapy equitably when clinically indicated.
The most precise post-launch question is therefore: Of the patients who should receive the medicine, how many can start it, how quickly, at what burden, through which barriers, and with what differences across patient groups?
If you’re assessing patient access after launch, we provide evidence-based insights into why eligible patients never start treatment or stop midway, across timeliness, usability, affordability, and equity. Talk to our market access team about patient access assessment, payer research, and real-world evidence support to turn coverage into realised access in routine care by filling out the form below or emailing at contact@iebrain.com.
For more information, visit our market access service page.
